Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Net Cash Flow (2016 - 2025)

Amicus Therapeutics' Net Cash Flow history spans 16 years, with the latest figure at $23.8 million for Q4 2025.

  • For the quarter ending Q4 2025, Net Cash Flow rose 202.49% year-over-year to $23.8 million, compared with a TTM value of -$12.7 million through Dec 2025, up 56.78%, and an annual FY2025 reading of -$12.7 million, up 56.78% over the prior year.
  • Net Cash Flow for Q4 2025 was $23.8 million at Amicus Therapeutics, down from $33.0 million in the prior quarter.
  • The five-year high for Net Cash Flow was $212.0 million in Q3 2021, with the low at -$146.9 million in Q4 2022.
  • Average Net Cash Flow over 5 years is $2.8 million, with a median of $5.1 million recorded in 2023.
  • Year-over-year, Net Cash Flow surged 417.32% in 2023 and then plummeted 22769.93% in 2025.
  • Tracing FOLD's Net Cash Flow over 5 years: stood at -$138.7 million in 2021, then dropped by 5.92% to -$146.9 million in 2022, then soared by 91.64% to -$12.3 million in 2023, then crashed by 88.88% to -$23.2 million in 2024, then soared by 202.49% to $23.8 million in 2025.
  • Per Business Quant, the three most recent readings for FOLD's Net Cash Flow are $23.8 million (Q4 2025), $33.0 million (Q3 2025), and -$32.7 million (Q2 2025).